Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.43 |
| ▸ | FPR2 | P25090 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18264290 | 1.00 | RORC (0.43) | RORCFPR2MAPTSMN1; SMN2TSHR | |
| SCHEMBL18264283 | 0.82 | FPR2 (0.63) | FPR2 | |
| SCHEMBL22068860 | 0.69 | CA1 (0.44) | RORCFPR2 | |
| SCHEMBL18264243 | 0.69 | FPR2 (0.60) | FPR2 | |
| SCHEMBL18043490 | 0.69 | EPHX2 (0.56) | SMN1; SMN2 | |
| SCHEMBL18043489 | 0.69 | EPHX2 (0.56) | SMN1; SMN2 | |
| SCHEMBL18106592 | 0.68 | FPR2 (0.66) | FPR2 | |
| SCHEMBL18264316 | 0.68 | FPR2 (0.66) | FPR2 | |
| SCHEMBL18264325 | 0.66 | MEN1 (0.38) | FPR2MAPTSMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL18264327 | 0.66 | MEN1 (0.38) | FPR2MAPTSMN1; SMN2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331884-B1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN SEIYAKU KK (JP) | 2020-06-17 | — | — | EP | disclosed |
| US-20180207153-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| EP-3331884-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kyorin Pharmaceutical Co., Ltd. (JP) | 2018-06-13 | — | — | EP | disclosed |
| WO-2016189876-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207153-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, SAAL1 | RORC 975/4885FPR2 2/4885MAPT 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.